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COST-EFFECTIVENESS OF NONINVASIVE MAGNETIC RESONANCE 
DIRECT THROMBUS IMAGING AND ULTRASONOGRAPHY FOR 
DIAGNOSING DISTAL DEEP VEIN THROMBOSIS
Patel V1, McGhan W2
1The University of Illinois at Chicago, Chicago, IL, USA, 2University of the Sciences in 
Philadelphia, Philadelphia, PA, USA
OBJECTIVES: Proper diagnosis of Deep Vein Thrombosis (DVT) at the earliest time 
is very important so that appropriate therapy can be initiated. Ultrasonography is the 
most widely used diagnostic technique. Noninvasive magnetic resonance direct throm-
bus imaging (MRDTI) is a new diagnostic technique that has higher sensitivity and 
speciﬁcity compared to Ultrasonography for distal deep vein thrombosis (DVT). The 
objective is to identify the most cost-effective strategy for diagnosis of distal deep vein 
thrombosis. METHODS: A decision-analysis model was constructed using TreeAge 
Pro software and analyzed using second-order Monte Carlo simulation technique. 
Diagnostic accuracy was calculated using Bayes’ revision method that utilized sensitiv-
ity and speciﬁcity of the diagnostic tests along with the pretest probability of develop-
ing the disease. Outcomes considered were costs, adverse events and quality of life. 
Quality-adjusted life years were calculated using life expectancy tables. Where appli-
cable, costs in pounds were converted to US dollars and adjusted through use of 
Consumer Price Index data from Bureau of Labor Statistics. Net beneﬁt of each 
strategy was analyzed at different willingness to pay (WTP) thresholds ($0 to 
$150,000) to determine the most cost-effective strategy. RESULTS: Noninvasive MRI 
is the optimal strategy for diagnosis of distal DVT at all WTP thresholds greater than 
$25,000. No diagnosis strategy was the most cost-effective strategy when threshold 
was below $25,000. Sensitivity analysis showed that noninvasive MRI remained cost-
effective even when all costs were varied by 25%. The model results were affected by 
the sensitivity of the diagnostic tests. CONCLUSIONS: For base-case scenario, non-
invasive MRI is the most cost-effective strategy. Considering the cost-effectiveness and 
the fact that ultrasonography has higher mortality compared to noninvasive MRI, 
employing noninvasive MRI appears to the optimal strategy. Health care providers 
should consider patient population distribution among the risk groups deﬁned by 
Wells score for generalizing the study results to their setting.
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COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF 
HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY 
DISEASE IN BRAZIL
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OBJECTIVES: The chronic kidney disease (CKD) is associated with an abnormally 
elevated level of phosphate in the blood, which contributes to the presence of vascular 
calciﬁcations, thus increasing the probability of the occurrence of cardiovascular 
events and death in these patients. The objective of this analysis was to evaluate the 
incremental cost-effectiveness of the use of sevelamer to manage hyperphosphatemia 
in Brazil METHODS: A Markov model was created to estimate the monthly costs 
and beneﬁts of the treatment with sevelamer or calcium tablets in patients with renal 
failure considering a temporary horizon of 60 months. The transition probabilities 
were taken from clinical trials identiﬁed through a systematic review of literature. The 
effectiveness measure considered was an increase in patient survival (months). Only 
direct costs were considered . Costs were calculated using 2009 prices and are 
expressed in US dollars. In addition, univariate sensitivity analysis and scenario 
changes were performed. The discount rate was 5%. RESULTS: The expected cost 
was US$37,477 for calcium and US$58,397 for sevelamer. Patients in calcium group 
would survive 51 months, compared to the sevelamer group (54 months). The Cost-
Effectiveness Ratio with calcium was $734 and with sevelamer was $1073 respec-
tively, and the incremental Cost-Effectiveness Ratio for the implementation of 
sevelamer vs. calcium was $6135 .(1 USD = 1.8 BRL$) CONCLUSIONS: Sevelamer 
is a cost-effective drug for the treatment of hyperphosphatemia in patients with CKD 
in the brazilian context.
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OBJECTIVES: The chronic kidney disease (CKD) is associated with an abnormally 
elevated level of phosphate in the blood, which contributes to the presence of vascular 
calciﬁcations, thus increasing the probability of the occurrence of cardiovascular 
events and death in these patients. The objective of this analysis was to evaluate the 
incremental cost-effectiveness of the use of sevelamer to manage hyperphosphatemia 
in Argentina METHODS: A Markov model was created to estimate the monthly costs 
and beneﬁts of the treatment with sevelamer or calcium tablets in patients with renal 
failure considering a temporal horizon of 60 months. The transition probabilities were 
taken from clinical trials identiﬁed through a systematic review of literature. The 
effectiveness measure considered was an increase in patient survival (months). Only 
direct costs were considered . Costs were calculated using 2009 prices and are 
expressed in US dollars. In addition, univariate sensitivity analysis and scenario 
changes were performed. The discount rate was 5%. Exchange rate was 3.6 Argentine 
pesos (ARS) per 1 US dollar. RESULTS: The expected cost was US$52,558 for calcium 
and US$69,678 for sevelamer. Patients in calcium group would survive 51 months, 
compared to the sevelamer group (54 months). The Cost-Effectiveness Ratio with 
calcium was US$1030 and with sevelamer was US$1280 respectively, and the incre-
mental Cost-Effectiveness Ratio for the implementation of sevelamer vs. calcium was 
US$5021. ICER of sensitivity analysis doesn’t change more than 10% of original 
scenario. CONCLUSIONS: Sevelamer is a cost-effective drug for the treatment of 
hyperphosphatemia in patients with CKD in the Argentinian context.
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COST-EFFECTIVENESS ANALYSIS OF CELECOXIB FOR THE 
MANAGEMENT OF LOW BACK PAIN AT THE SOCIAL SECURITY 
MEXICAN INSTITUTE
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Muciño-Ortega E3, Mould-Quevedo JF3
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OBJECTIVES: The aim of this research was to estimate from an institutional perspec-
tive the cost-effectiveness of celecoxib against other usual analgesics for the treatment 
of adult patients with low-back pain. METHODS: A complete economic evaluation 
was conducted using a Markov model. Four health-states were used by the Markov 
model to assess the disease history within a 12-month time horizon. Treatments used 
in the evaluation were: Celecoxib 200 mg/day, naproxen 1 gr/day (oral) for 14 days; 
diclofenac 150 mg/day (intramuscular) for two days followed by diclofenac 200 mg/
day (oral) for 12 days; tramadol/acetaminophen 75 mg/day (oral) for 14 days and 
acetaminophen 1500 mg/day (oral) for 14 days. Effectiveness measures were: mean 
reduction of pain >50% vs. baseline (through visual analog scale questionnaire) and 
mean reduction in days of hospitalization. Hospital records were collected in several 
institutional Mexico City hospitals (n = 15,723). Unit costs were obtained from clinical 
records and ofﬁcial databases from patients seen in the Social Security Mexican 
Institute. Probabilistic sensitivity analyses were performed employing bootstrapping 
techniques and acceptability curves were constructed. RESULTS: Celecoxib treatment 
showed the highest mean pain reduction with 57% [CI95% 55–58%] followed by 
tramadol/acetaminophen with 46% [45–48%] and acetaminophen with 42% [40–
43%]. The celecoxib-treated group also showed the lowest rate of hospitalization 0.17 
[0.16–0.18] followed by tramadol/acetaminophen with 0.19 [0.19–0.20] and naproxen 
with 0.23 [0.23–0.24]. Celecoxib showed an ICER of US$471.71 for the mean pain 
reduction and US$1,088.48 for the mean reduction of hospitalized days measurement 
against diclofenac (case base). The latter was conﬁrmed by Monte Carlo ﬁrst-order 
simulations and acceptability curves. CONCLUSIONS: Celecoxib was more cost-
effective as a treatment for adult patients with low back-pain (higher effectiveness 
with low annual costs) than other usual analgesics.
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OBJECTIVES: The current study aimed to compare the lifetime health outcomes and 
cost-effectiveness of bortezomib plus melphalan and prednisone (VMP) relative to 
melphalan and predisone alone (MP), and indirectly to thalidomide plus MP (MPT), 
for the initial treatment of multiple myeloma (MM) in the non-transplant setting. 
METHODS: A Markov model from a US payer’s perspective was developed. Simula-
tions were performed on hypothetical cohorts of newly diagnosed MM patients ineli-
gible for transplant. The model included seven health states representing periods of 
treatment response, treatment-free interval, progressive disease, second-line treatment, 
and death. Monthly transition probabilities were estimated from patient-level phase 
III VISTA trial data for VMP and MP (June 15, 2007 data cut-off) and from the 
published phase III IFM 99–06 trial for MPT (Facon et al, Lancet 2007). Costs 
included per-protocol drug and medical costs, treatment-related adverse events, sec-
ond-line treatment, and resource utilization during treatment-free interval and pro-
gressive disease. All costs were adjusted to 2009 US dollars. State-speciﬁc utility 
estimates were derived from patient-level EQ-5D data from VISTA using US-speciﬁc 
weights. Health outcomes were expressed in life-years (LYs) and quality-adjusted 
life-years (QALYs). Both cost and health outcomes were discounted at 3%. RESULTS: 
The model estimated 4.187 LYs (2.994 QALYs) with VMP versus 2.864 LYs (2.049 
QALYs) with MP and 4.140 LYs (2.951 QALYs) with MPT. Lifetime direct medical 
costs are $110,870 for VMP versus $57,864 for MP and $129,902 for MPT. Cost 
per LY and QALY gained with VMP versus MP is $40,051 and $56,109, respectively. 
VMP is dominant versus MPT, costing 17.7% less and providing slightly more 
QALYs. CONCLUSIONS: The incremental cost-effectiveness of VMP versus MP is 
within the generally accepted range of $50,000 to $100,000 per QALY, suggesting 
that VMP is cost-effective versus MP in the US. VMP is dominant versus MPT, yielding 
lower costs and better health outcomes.
